August 13, 2025 — Leads & Copy — Allogene Therapeutics, Inc. (Nasdaq: ALLO) provided corporate updates and reported financial results for the quarter ended June 30, 2025. The company is advancing its ALPHA3 trial, initiating clinical enrollment in autoimmune indications with ALLO-329, and aligning with the FDA on a pivotal path forward for ALLO-316 in solid tumors.
The pivotal Phase 2 ALPHA3 trial with Cemacabtagene Ansegedleucel (Cema-Cel) is proceeding as a two-arm randomized trial comparing cema-cel after standard Fludarabine and Cyclophosphamide (FC) lymphodepletion vs. observation. More than 50 sites are activated across the U.S. and Canada, with additional international expansion underway. The scheduled futility analysis remains on track for 1H 2026.
The Phase 1 RESOLUTION Trial with ALLO-329 in Autoimmune Disease (AID) has been initiated, with a basket trial in rheumatology. Proof-of-concept data is planned for 1H 2026.
Updated Phase 1B results for the Phase 1 TRAVERSE Trial with ALLO-316 in Renal Cell Carcinoma (RCC) were presented at ASCO 2025, highlighting clinical responses and the potential of the Dagger® Technology Platform. The company has aligned with the FDA on a pivotal trial design.
Allogene ended Q2 2025 with $302.6 million in cash, cash equivalents, and investments, with a cash runway projected into 2H 2027.
Conference Call and Webcast Scheduled for Today at 2:00 PM PT/5:00 PM ET.
Christine Cassiano, EVP, Chief Corporate Affairs & Brand Strategy Officer, Christine.Cassiano@allogene.com
Source: Allogene Therapeutics, Inc.
